Results 11 to 20 of about 4,643,128 (344)

Antimalarial drug discovery: progress and approaches

Nature Reviews Drug Discovery, 2023
Recent antimalarial drug discovery has been a race to produce new medicines that overcome emerging drug resistance, whilst considering safety and improving dosing convenience.
Jair L. Siqueira-Neto, Kathryn J. Wicht, K. Chibale, J. Burrows, D. Fidock, E. Winzeler   +5 more
semanticscholar   +3 more sources

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.

Lancet, The, 2018
BACKGROUND Lifelong HIV antiretroviral therapy (ART) has prompted an interest in two-drug regimens to minimise cumulative drug exposure and toxicities. The safety, tolerability, and efficacy of dolutegravir and rilpivirine suggest potential compatibility
J. Llibre, C. Hung, C. Brinson, F. Castelli, P. Girard, L. Kahl, Elizabeth A Blair, Kostas Angelis, B. Wynne, Kati Vandermeulen, M. Underwood, Kim Smith, M. Gartland, M. Aboud   +13 more
semanticscholar   +3 more sources

Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions

Respirology, 2017
J. Galli, A. Pandya, Michelle Vega-Olivo, C. Dass, Huaqing Zhao, G. Criner   +5 more
semanticscholar   +3 more sources

Drug tolerability: How much ambiguity can be tolerated? A systematic review of the assessment of tolerability in clinical studies

British Journal of Clinical Pharmacology, 2021
Drug tolerability refers to the degree to which drugs' overt adverse effects can be tolerated by patients. The tolerability profile is of comparative importance to its efficacy and safety, as it largely determines adherence to treatment and ultimately ...
V. Stanulović, M. Hodolič, D. Mitsikostas, D. Papadopoulos   +3 more
semanticscholar   +1 more source

Understanding Antipsychotic Drug Tolerability

The Annals of Pharmacotherapy, 2001
C. Alderman
openaire   +2 more sources

Tandem-Cleavage Linkers Improve the In Vivo Stability and Tolerability of Antibody-Drug Conjugates

bioRxiv, 2021
Although peptide motifs represent the majority of cleavable linkers used in clinical-stage antibody-drug conjugates (ADCs), the sequences are often sensitive to cleavage by extracellular enzymes, such as elastase, leading to systemic release of the ...
S. Chuprakov, A. Ogunkoya, Robyn M. Barfield, M. Bauzon, Colin Hickle, Y. Kim, Dominick Y. Yeo, Fangjiu Zhang, David Rabuka, Penelope M. Drake   +9 more
semanticscholar   +1 more source

Impact of Pharmacogenomics in Clinical Practice

Pharmaceuticals, 2023
Polymorphisms of genes encoding drug metabolizing enzymes and transporters can significantly modify pharmacokinetics, and this can be associated with significant differences in drug efficacy, safety, and tolerability.
Nicola Principi, Kyriakoula Petropulacos, Susanna Esposito   +2 more
doaj   +1 more source

A comparative evaluation of the efficacy and safety of Latanoprost-Optic and Xalatan used as monotherapy and combined with Dorzolamide-Optic for primary open-angle glaucoma under clinical practice conditions

Российский офтальмологический журнал, 2023
The number of ophthalmic antihypertensive drugs available in Russia is steadily increasing, which complicates the choice to be made by ophthalmologist practitioners.
D. P. Novikov, O. A. Frolov, A. S. Pokrovsky, V. V. Novikova   +3 more
doaj   +1 more source

Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability

Cancers, 2023
Simple Summary Antibody-drug conjugates (ADC) are a rapidly expanding class of anti-cancer drugs, with twelve agents in current clinical use. Despite recent successes, many ADCs fail during clinical development due to excessive toxicities and unfavorable
T. D. Nguyen, Brandon M Bordeau, J. Balthasar   +2 more
semanticscholar   +1 more source

Eletriptan in the management of acute migraine. An update on the evidence for efficacy, safety, and consistent response [PDF]

, 2016
Migraine is a multifactorial, neurological and disabling disorder, also characterized by several autonomic symptoms. Triptans, selective serotonin 5-HT1B/1D agonists, are the first-line treatment option for moderate-to-severe headache attacks.
Capi, Matilde, Curto, Martina, De Andrés, Fernando, Gentile, Giovanna, Lionetto, Luana, Martelletti, Paolo, Negro, Andrea   +6 more
core   +1 more source